Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting
January 20, 2022
From Benzinga
FDA Gives Green Signal To Compass Therapeutics' Mid-Stage Biliary Tract Cancer Trial In US
January 20, 2022
Tickers
CMPX
From Benzinga
Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients
January 19, 2022
From Benzinga
Cardiff Oncology Slumps On New Data From Lead Program In Metastatic Colorectal Cancer
January 19, 2022
Tickers
CRDF
From Benzinga
RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance
January 13, 2022
Tickers
RDHL
From Benzinga
Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate
January 13, 2022
Tickers
PCVX
From Benzinga
Annexon's Interim Mid-Stage Results On Huntington's Disease Candidate Fails To Cheer
January 05, 2022
Tickers
ANNX
From Benzinga
Mereo BioPharma's Alvelestat Shows Improvement In COVID-19 Severity
December 22, 2021
Tickers
MREO
From Benzinga
Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
December 21, 2021
Tickers
ADVM
From Benzinga
From Benzinga
Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient
December 20, 2021
Tickers
CANF
From Benzinga
Bellerophon Stock Surges After Positive Data From Sarcoidosis-Associated Pulmonary Hypertension Trial
December 17, 2021
Tickers
BLPH
From Benzinga
UniQure Shares Fall After Clinical Update From Huntington's Disease Gene Therapy Trial
December 16, 2021
Tickers
QURE
From Benzinga
From Benzinga
GeoVax Initiates Phase 2 Trial For COVID-19 Vaccine Booster
December 15, 2021
Tickers
GOVX
From Benzinga
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
December 15, 2021
From Benzinga
Final Data Reaffirms Efficacy Of Pfizer's COVID-19 Antiviral Treatment
December 14, 2021
Tickers
PFE
From Benzinga
Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update
December 14, 2021
Tickers
APTO
From Benzinga
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
December 14, 2021
Tickers
GILD
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.